Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TARO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TARO, but not buy additional shares or sell existing shares.
View TARO analyst ratings or view top-rated stocks.

1 brokers have issued twelve-month price targets for Taro Pharmaceutical Industries' shares. Their TARO share price targets range from $43.00 to $43.00. On average, they predict the company's share price to reach $43.00 in the next year. This suggests a possible upside of 1.8% from the stock's current price.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.

Taro Pharmaceutical Industries' stock was trading at $41.78 on January 1st, 2024. Since then, TARO shares have increased by 1.1% and is now trading at $42.25.
View the best growth stocks for 2024 here.

Taro Pharmaceutical Industries saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 39,800 shares, a drop of 32.0% from the March 15th total of 58,500 shares. Based on an average daily trading volume, of 51,900 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.5% of the company's stock are short sold.
View Taro Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TARO earnings forecast.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Thursday, January, 25th. The company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.26. The firm had revenue of $157.15 million for the quarter, compared to the consensus estimate of $154.90 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 3.26% and a net margin of 7.48%.

ARK Israel Innovative Technology ETF holds 50,932 shares of TARO stock, representing 1.98% of its portfolio.

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.